| 구분 |
보고서 (영문) |
| 제약/바이오/임상시험 |
EMA CHMP Decision for Nezglyal Recommends Refusal of Marketing Authorization |
| Novartis Will See Modest Boost to Blood Cancer Portfolio with MorphoSys Acquisition |
| Epetraborole Phase III Enrollment Pause Sets Back NTM Late-Stage Pipeline |
| Beacon Therapeutics Unveils Promising Interim Results for Gene Therapy AGTC-501 |
| ViiV Healthcare and GSK’s Cabenuva Could Reduce Poor Treatment Adherence in HIV |
| Biogen Discontinues Aduhelm to Focus on Leqembi for Alzheimer’s Disease |
| 질환별 |
2023–24 Seasonal Flu Activity Remains Elevated |
| Non-Small Cell Lung Cancer (NSCLC): Epidemiology Forecast to 2032 |
| Will Smart Technology Revolutionize Drug Delivery for Ulcerative Colitis Patients? |
| Central Nervous System Takes the Lead in Global Drug Withdrawals |
| Burden of Dental Diseases Rises Sharply in the UK |
| 컨퍼런스/심포지엄/학회/기타 |
Conference Organizing Tool - ADPD 2024 |
| Conference Organizing Tool – European Lupus Meeting (ELM) 2024 - Interim |
